0001104659-23-048480.txt : 20230421 0001104659-23-048480.hdr.sgml : 20230421 20230421170622 ACCESSION NUMBER: 0001104659-23-048480 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230417 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230421 DATE AS OF CHANGE: 20230421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gardiner Healthcare Acquisitions Corp. CENTRAL INDEX KEY: 0001858912 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 862899992 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41185 FILM NUMBER: 23837164 BUSINESS ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 BUSINESS PHONE: 216-633-6708 MAIL ADDRESS: STREET 1: 3107 WARRINGTON ROAD CITY: SHAKER HEIGHTS STATE: OH ZIP: 44120 8-K 1 tm2313384d1_8k.htm FORM 8-K
0001858912 false 0001858912 2023-04-17 2023-04-17 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-04-17 2023-04-17 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-04-17 2023-04-17 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-04-17 2023-04-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(D) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 21, 2023 (April 17, 2023)

 

GARDINER HEALTHCARE ACQUISITIONS CORP.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-41185   86-2899992
(State or other jurisdiction of
incorporation)
  (Commission
File Number)
  (I.R.S. Employer
Identification No.)

 

3107 Warrington Road
Shaker Heights, Ohio
  44120
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (216) 633-6708

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on 
which registered
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant   GDNRU   The Nasdaq Stock Market LLC
Shares of common stock, par value $0.0001 per share   GDNR   The Nasdaq Stock Market LLC
Redeemable warrants   GDNRW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On April 17 and April 18, 2023, Gardiner Healthcare Acquisitions Corp. (the “Company”) issued unsecured promissory notes (each, a “Promissory Note” and, collectively, the “Promissory Notes”) to each of Marc F. Pelletier, the Chief Executive Officer of the Company, and Moss Ridge PTY LTD. Pursuant to the Promissory note with Mr. Pelletier, the Company borrowed $20,000 for expenses related to the Company’s operations, and repaid Mr. Pelletier on April 19, 2023. Pursuant to the Promissory Note with Moss Ridge PTY LTD, the Company borrowed the amount of $30,000 on April 18, 2023 for costs, fees and expenses related to the Company’s operations, including those relating to the preparation, negotiation and consummation of an intended initial business combination (the “Business Combination”). All unpaid principal under the Promissory Note with Moss Ridge PTY LTD will be due and payable in full on the earlier of (i) the Maturity Date and (ii) the date on which the Company consummates a Business Combination.

 

A copy of the form of Promissory Note is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference, and the foregoing description of the Promissory Notes is qualified in its entirety by reference thereto.

  

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth above in Item 1.01 of this Current Report on Form 8-K is incorporated by reference herein.

 

Item 8.01 Other Events.

 

On April 21, 2023, the Company issued a press release announcing its intention to extend the date by which the Company must consummate a Business Combination, pursuant to its Amended and Restated Certificate of Incorporation and Investment Management Trust Agreement, each as amended, from April 27, 2023 to May 27, 2023. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit   Description
10.1   Form of Promissory Note.
99.1   Press Release, dated April 21, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Gardiner Healthcare Acquisitions Corp.
     
Date: April 21, 2023 By: /s/ Marc F. Pelletier
    Name: Marc F. Pelletier
    Title: Chief Executive Officer

 

 

EX-10.1 2 tm2313384d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

THE OFFER AND SALE OF THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

PROMISSORY NOTE

 

Principal Amount: up to U.S. $[20,000/30,000] Dated as of April __, 2023
  Shaker Heights, Ohio

 

Gardiner Healthcare Acquisitions Corp., a Delaware corporation and blank check company (the “Maker”), promises to pay to the order of ____________________ or its registered assigns or successors in interest (together, the “Payee”), the principal sum of up to [Twenty Thousand and 00/100/Thirty Thousand and 00/100] U.S. Dollars in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by check or wire transfer of immediately available funds to such account as Payee may from time to time designate by Notice (as defined in Section 9) to Maker in accordance with the provisions of this Note.

 

1. Principal. The principal balance of this Note shall be payable by Maker on the earlier of: (i) June 27, 2023 (the “Maturity Date”) or (ii) the date on which the Maker consummates an initial business combination (the “Business Combination”). The principal balance may be prepaid at any time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of Maker, be obligated personally for any obligations or liabilities of Maker hereunder.

 

2. Interest. No interest shall accrue on the unpaid principal balance of this Note.

 

3. [Intentionally Omitted.]

 

4. Application of Payments. All payments shall be applied, first, to payment in full of any costs incurred in the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, second, to the payment in full of any late charges, and third, to the reduction of the unpaid principal balance of this Note.

 

5. [Intentionally Omitted.]

 

6. Events of Default. The following events shall constitute an event of default (“Event of Default”):

 

6.1 Failure to Make Required Payments. The failure by Maker to pay the principal amount due pursuant to this Note within five business days of the Maturity Date.

 

6.2 Voluntary Bankruptcy, Etc. The: (a) commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law; (b) consent by Maker to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker for any substantial part of its property, (c) making by Maker of any assignment for the benefit of creditors; (d) the failure of Maker generally to pay its debts as such debts become due; or (e) taking of any corporate action by Maker in furtherance of any of the foregoing events described in Section 6.2(a)Section 6.2(d).

 

6.3 Involuntary Bankruptcy, Etc. The: (a)(i) entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any applicable bankruptcy, insolvency or other similar law, (ii) appointment of a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or (iii) the ordering of the winding-up or liquidation of Maker’s affairs; and (b) continuance of any such decree, appointment, or order unstayed and in effect for a period of 60 consecutive days.

 

 

 

 

7. Remedies.

 

7.1 Upon the occurrence of an Event of Default specified in Section 6.1, Payee may, by Notice to Maker, declare this Note to be due immediately and payable by Maker, whereupon the unpaid principal amount of this Note, and all other amounts payable hereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, notwithstanding anything contained herein or in the documents evidencing the same to the contrary.

 

7.2 Upon the occurrence of an Event of Default specified in Section 6.2 and Section 6.3, the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall automatically and immediately become due and payable by Maker, in all cases without any action on the part of Payee.

 

8. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive: (a) presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note; (b) all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note; and (c) all benefits that might accrue to Maker by virtue of any present or future laws (i) exempting any property, real or personal, or any part of the proceeds arising from any sale of any such real or personal property, from attachment, levy or sale under execution, or (ii) providing for any stay of execution, exemption from civil process, or extension of time for payment. Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof or any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

 

9. Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that Maker’s liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee. Maker consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note. Maker agrees that additional makers, endorsers, guarantors, or sureties may become parties hereto without either any Notice to Maker or any bearing on Maker’s liability hereunder.

 

10. Notices. All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a “Notice”) shall be in writing and addressed to the parties at the addresses set forth on the first page of this Agreement (or to such other address that may be designated by the receiving party from time to time in accordance with this Section 10). A Notice shall be deemed to have been given (a) when delivered by hand (with written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by facsimile or email (with confirmation of transmission) if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient; or (d) on the third day after the date mailed, by certified or registered mail (in each case, return receipt requested, postage pre-paid).

 

11. Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

 

12. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 

13. Trust Waiver. Notwithstanding anything herein to the contrary, Payee hereby waives any and all right, title, interest or claim of any kind (each, a “Claim”) in or to any distribution of or from the trust account (the “Trust Account”), in which the proceeds of both the (a) initial public offering of the Maker (the “IPO”) (including the deferred underwriters discounts and commissions) and (b) sale of the warrants issued in a private placement to occur at the closing of the IPO were deposited, as described in greater detail in the Registration Statement on Form S-1 and prospectus filed with the Securities and Exchange Commission in connection with the IPO. Payee hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever.

 

14. Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of both Maker and Payee.

 

- 2 -

 

 

15. Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or otherwise) without the prior written consent of the other party hereto. Any attempted assignment without the required consent shall be void.

 

[Signature page follows]

 

- 3 -

 

 

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above written.

 

  Gardiner Healthcare Acquisitions Corp.
     
By:
    Name: Marc F. Pelletier
    Title: Chairman and Chief Executive Officer

 

[Signature Page to Promissory Note]

 

 

 

EX-99.1 3 tm2313384d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

PRESS RELEASE

 

Company Release – April 21, 2023 – 5:00 PM ET

 

Gardiner Healthcare Acquisitions Corp. Announces Extension

 

SHAKER HEIGHTS, Ohio - Gardiner Healthcare Acquisitions Corp. (the “Company”) announced, in accordance with Section 2(i) of its Investment Management Trust Agreement with Continental Stock Transfer & Trust Company, as amended (the “Trust Agreement”), that at least five days prior to April 27, 2023, the Company received notice from Gardiner Healthcare Holdings, LLC (the “Gardiner Sponsor”) that the Gardiner Sponsor intends to extend the deadline to consummate an initial business combination pursuant to the Trust Agreement and the Board of Directors of the Company has approved such extension. Furthermore, the Company received notice from the Gardiner Sponsor that the Gardiner Sponsor intends to deposit funds into the trust account under the Trust Agreement on or prior to April 27, 2023 to extend the deadline from April 27, 2023 to May 27, 2023.

 

The Company is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on the healthcare or healthcare related industries. The Company is sponsored by the Gardiner Sponsor, Chardan Gardiner LLC, and CCMAUS Pty Ltd.

 

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (“Securities Act”). This announcement is being issued in accordance with Rule 135 under the Securities Act.

 

Contact: Marc F. Pelletier, PhD

ir@gardinerhealthcare.com

 

 

 

EX-101.SCH 4 tmb-20230417.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 tmb-20230417_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 tmb-20230417_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member] Shares Of Common Stock Par Value 0. 0001 Per Share Included As Part Of Units [Member] Redeemable Warrants Included As Part Of Units [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Redeemable warrants Shares of common stock, par value $0.0001 per share Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant EX-101.PRE 7 tmb-20230417_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 17, 2023
Document Information [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 17, 2023
Entity File Number 001-41185
Entity Registrant Name GARDINER HEALTHCARE ACQUISITIONS CORP.
Entity Central Index Key 0001858912
Entity Tax Identification Number 86-2899992
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 3107 Warrington Road
Entity Address, City or Town Shaker Heights
Entity Address, State or Province OH
Entity Address, Postal Zip Code 44120
City Area Code 216
Local Phone Number 633-6708
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]  
Document Information [Line Items]  
Title of 12(b) Security Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant
Trading Symbol GDNRU
Security Exchange Name NASDAQ
Shares Of Common Stock Par Value 0. 0001 Per Share Included As Part Of Units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Shares of common stock, par value $0.0001 per share
Trading Symbol GDNR
Security Exchange Name NASDAQ
Redeemable Warrants Included As Part Of Units [Member]  
Document Information [Line Items]  
Title of 12(b) Security Redeemable warrants
Trading Symbol GDNRW
Security Exchange Name NASDAQ
XML 9 tm2313384d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001858912 2023-04-17 2023-04-17 0001858912 tmb:UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember 2023-04-17 2023-04-17 0001858912 tmb:SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember 2023-04-17 2023-04-17 0001858912 tmb:RedeemableWarrantsIncludedAsPartOfUnitsMember 2023-04-17 2023-04-17 iso4217:USD shares iso4217:USD shares 0001858912 false 8-K 2023-04-17 GARDINER HEALTHCARE ACQUISITIONS CORP. DE 001-41185 86-2899992 3107 Warrington Road Shaker Heights OH 44120 216 633-6708 false false false false Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant GDNRU NASDAQ Shares of common stock, par value $0.0001 per share GDNR NASDAQ Redeemable warrants GDNRW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,J(E58'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #*B)56ZL,;]^\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>.DEAAZC+91,GD)"8!.(6)=X6K6FCQ*C=V].6K1."!^ 8^\_G MSY)K&Y7M$KZD+F(BC_EN"$V;E8UK=B2*"B#;(P:3RS'1CLU]EX*A\9D.$(T] MF0."Y'P% _/3Z_SNH5O M,YG6XO@K>T7GB&MVG?Q6;;:[1Z8EEU7![PLI=E(HOE+BX6-R_>%W$PZ=\WO_ MCXVO@KJ&7W>AOP!02P,$% @ RHB55IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #*B)56U#"KUIH% .&@ & 'AL+W=OC\*SA&"(6LT ;"0HO]VS XM@H <>W MK6BC_$XS\/GQD_I%H&( M5?&?K+?7.@T2Y$J+9#L8"!*>;E[IPS80^PSPM@.\@GOS107E.=6T=RK%FDAS M-:B9@^)6B]$ QU.3E9F6\"F'<;HW$/=,GC8U2)DWFL%VV/O-,&_'L'XFCXC; M.2">X_G_'MX$@A+#*S&\0L_?H7K_]XK:=/Q%@OP3V,74+/'_,6!4#HE3V$8&U]/)$0+< M+8&[^P /(+V2QE"?(7L@']EC%3*NY$ 5G+C<+*)W3)*-;2N,T%J"BS?U[PG+9$^DN.=I M4!U.7//Z$D.S1N'BG?Y[M(E0&JKY+Y[MGH&X8JOE>@[&9LW#Q7M^D<@^+"EW MH^ "GMO&0*Q5N'B?_R0"B,DD$BGF%34B;=\_;'><+D9DS<+%N_RMY%JS% *3 M)'FZ[7"JD@H7JG-ZU]J!BW?QF8AYP#54-[F"Z2TYC2MY<)5:'NL#+MZV)Y(= M!A >!O6U69#!F@@*^WJYW)$_7*^.S+,.X.$]^@792*DL5,9ZK>$*&=9DO-8;;.)0FWDMLS4?#_>..==QD1W7 M^WWQ!YFQ((>>6SWY<:7_^,M=I,[B8%GC5HAROK0!KH-[)&U0M:J*O M??9BK=7'/? 'JK9&:9OE'RE,[ ZL]_JX5=877XV *3Z,Q'JM7[,1VKOV:H1J M:\]_]G -=]2I[7BWFXZG7EE<^!>]=J):2_3?P!+]M[!$WUJB_],LL49I^L*X ML(VV;YW+_Z_.52-@BN<60['.Y?\LYZH1VET]S6=/]\TO)5?4+-<5B=D2E)RC M#B1!;GY\V)QHD14/_!=":Y$4AQ&CL.6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQN MZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[) MWMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBM MNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^, MX_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M* M'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1 MJP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF M<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD\%G'!QR> M(W?#$T%^@2O&+(=/EB> MN$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM M0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S' M$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@//GL?)=-[ M*CG_5U/\!%!+ P04 " #*B)56EXJ[', 3 @ "P %]R96QS+RYR M96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY M/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL M/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J. MW&,EC'%BM/XU@LD/['X 4$L#!!0 ( ,J(E5:JQ"(6,P$ "(" / M>&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0B MB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C!VWA'#02= M5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y M8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; @L4?>M>9 M_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9( M;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+( M)FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>R MY1AQ_)[E#U!+ P04 " #*B)56)!Z;HJT #X 0 &@ 'AL+U]R96QS M+W=O[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E% M9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ RHB55F60>9(9 0 SP, !, !;0V]N M=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z3 M9UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A M.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+, M:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5C ME>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68* MR,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/ M^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " #*B)56!T%- M8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ M 0(4 Q0 ( ,J(E5;JPQOW[P "L" 1 " :\ !D M;V-0&UL4$L! A0#% M @ RHB55M0PJ]::!0 #AH !@ ("!#@@ 'AL+W=O&UL4$L! A0#% @ RHB5 M5I>*NQS $P( L ( !NA %]R96QS+RYR96QS4$L! M A0#% @ RHB55JK$(A8S 0 (@( \ ( !HQ$ 'AL M+W=O@3 !;0V]N E=&5N=%]4>7!E&UL4$L%!@ ) D /@( #(5 $! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 4 23 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gardinerhealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2313384d1_8k.htm tm2313384d1_ex10-1.htm tm2313384d1_ex99-1.htm tmb-20230417.xsd tmb-20230417_def.xml tmb-20230417_lab.xml tmb-20230417_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2313384d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 29 }, "contextCount": 4, "dts": { "definitionLink": { "local": [ "tmb-20230417_def.xml" ] }, "inline": { "local": [ "tm2313384d1_8k.htm" ] }, "labelLink": { "local": [ "tmb-20230417_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230417_pre.xml" ] }, "schema": { "local": [ "tmb-20230417.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 3, "memberStandard": 0, "nsprefix": "tmb", "nsuri": "http://gardinerhealthcare.com/20230417", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2313384d1_8k.htm", "contextRef": "From2023-04-17to2023-04-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://gardinerhealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2313384d1_8k.htm", "contextRef": "From2023-04-17to2023-04-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "tmb_RedeemableWarrantsIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Redeemable Warrants Included As Part Of Units [Member]" } } }, "localname": "RedeemableWarrantsIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230417", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares Of Common Stock Par Value 0. 0001 Per Share Included As Part Of Units [Member]" } } }, "localname": "SharesOfCommonStockParValue0.0001PerShareIncludedAsPartOfUnitsMember", "nsuri": "http://gardinerhealthcare.com/20230417", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "tmb_UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant", "label": "Units, each consisting of one share of common stock, par value $0.0001 per share, and one redeemable warrant [Member]" } } }, "localname": "UnitsEachConsistingOfOneShareOfCommonStockParValue0.0001PerShareAndOneRedeemableWarrantMember", "nsuri": "http://gardinerhealthcare.com/20230417", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://gardinerhealthcare.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001104659-23-048480-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-048480-xbrl.zip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end